Evaluation Addressing the Complexities of Vitiligo: Targeted Strategies to Improve Quality of Life Evaluation HMP Education would appreciate your feedback on the quality and impact of this activity.Please answer the following questions, some of which include a 5-point Likert scale (5 = strongly agree/excellent/great deal; 1 = strongly disagree/poor/very little). To what extent are you able to better achieve each of the following learning objectives? Outline the prevalence, impact, and disease burden of vitiligo 5 4 3 2 1 Describe the significance of the JAK-STAT pathway in vitiligo 5 4 3 2 1 Evaluate newer and emerging treatments and recommended protocols for segmental and nonsegmental vitiligo 5 4 3 2 1 Integrate strategies to optimize multidisciplinary care team efforts to care for patients with vitiligo 5 4 3 2 1 Please rate the faculty on the following: Seemal Desai, MD: Knowledge, expertise, and teaching ability 5 4 3 2 1 Please rate the following components relating to this activity: Content 5 4 3 2 1 Relevance to your practice 5 4 3 2 1 Educational format 5 4 3 2 1 Audience-participation portions (eg., Q&A, polling, pre/post-testing) 5 4 3 2 1 Resources and/or other materials supporting the activity 5 4 3 2 1 Overall 5 4 3 2 1 Therapeutic recommendations presented in this activity did not encourage inappropriate or excessive use of products/devices. Agree Disagree How many patients with Vitiligo do you see during a typical week? 0 patients 1-10 patients 11-20 patients 21-30 patients More than 30 patients Do you feel like there were any new data presented? Yes, please specify: No Did you learn anything new? Yes, please specify: No Did you gain confidence on the new information? Yes, why? No, why? Did this program include opportunities to learn as a part of a healthcare team? Yes, please specify: No In the US, approximately what percentage of individuals with vitiligo are estimated to be undiagnosed? 20% 30% 40% 50% Which of the following cytokines is involved in JAK/STAT initiation and contributes to vitiligo pathophysiology? IFN-γ IL-17 IL-12 TNF-α In two phase 2 trials, which of the following demonstrated improved repigmentation of nonsegmental vitiligo lesions through 52 weeks of follow-up? Baricitinib Ifidancitinib Ruxolitinib Tofacitinib How confident are you now in your ability to implement strategies to improve recognition and optimal multidisciplinary care for vitiligo management? Very confident Confident Somewhat confident Not very confident Not at all confident Do you intend to make any additional changes to your practice as a result of information gained from this activity? Please be specific. Yes, please describe: No What challenges or barriers outside of your control may prevent you from changing your practice? Adverse effects of available treatments Affordability/cost Institutional policy Insurance/formulary Lack of patient education/engagement Limited resources/time Need more information on optimal management strategies Outdated or unclear guidelines Patient adherence Other: How might future activities help you address those barriers? 255 characters max The information presented in this activity did not serve to advance a proprietary interest of any commercial entity. Agree Disagree Based on my participation in this activity, I anticipate I will more often: (select all that apply) Employ multidisciplinary strategies and approaches to vitiligo care Evaluate recent and emerging data on novel agents Evaluate the impact and burden of vitiligo on my patients Remain apprised of new and emerging treatments for vitiligo Review current protocols for the care of segmental and non-segmental vitiligo Utilize JAK/STAT inhibitors for the treatment of vitiligo with appropriate patients Other (please specify): Previous